Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2022 - 09 - 10 crawled time : 08:20 save search
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
Published: 2022-09-10 (Crawled : 08:20) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100
Published: 2022-09-10 (Crawled : 08:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
skyrizi trials skin week 100 results
Quhuo Files Its Annual Report on Form 20-F
Published: 2022-09-10 (Crawled : 08:20) - prnewswire.com
QH | $0.6144 -5.17% 41K
|
Technology Services
| Email alert
Add to watchlist
report
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
Published: 2022-09-10 (Crawled : 08:20) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
cosentyx trials novartis
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
Published: 2022-09-10 (Crawled : 08:20) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
| Email alert
Add to watchlist
treatment drug psoriasis food plague
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
Published: 2022-09-10 (Crawled : 08:20) - globenewswire.com
PNT | $13.68 2.63% 0.15% 0
|
| Email alert
Add to watchlist
biopharma trial
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
Published: 2022-09-10 (Crawled : 08:20) - globenewswire.com
IMTX | $10.26 0.29% 0.29% 440K
|
Health Technology
| Email alert
Add to watchlist
ima402 candidate preclinical set
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
Published: 2022-09-10 (Crawled : 08:20) - globenewswire.com
ADAG | $2.53 -0.37% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
adg126 safebody
Gainers vs Losers
| 63% | 37% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.